Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 436 participants.
Also called NCT07030621
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 436 participants
- Sponsor
- Registry
-
NCT07030621
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07030621. Randomized; double masking; primary purpose treatment. Start 2025-07-01 (anticipated); primary completion 2027-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
- Acronym
- STARS
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Semaglutide 0.5 mg
- Intervention (Drug)
- Normal Saline
- Lead sponsor
- RenJi Hospital
Record details
- Record id
cardio:ct-nct07030621- Content hash
b73f1855e192bd512b41deb491ac9b102057974267b692ffc3355b61fdf72516